ArticleHepatology (Baltimore, Md.)2012
Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis.
Article in Hepatology (Baltimore, Md.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- MicroRNAs during Echinococcus spp. infection: a comprehensive systematic review and implications for diagnosis and therapy.Parasites & vectors · 2026Pooled it
- Extrahepatic autoimmune conditions associated with primary biliary cirrhosis.Clinical reviews in allergy & immunology · 2015Pooled it
- Austrian Society of Gastroenterology and Hepatology (ÖGGH) consensus on primary biliary cholangitis.Wiener klinische Wochenschrift · 2026Article
- Autoantibodies in the diagnostics, prognostics and follow-up of primary biliary cholangitis.Journal of translational autoimmunity · 2026Review
- Cell-specific epigenome-wide DNA methylation in peripheral CD4(+) lymphocytes from patients with primary biliary cholangitis.Journal of translational autoimmunity · 2025Article
- Clinical management of autoimmune liver diseases: juncture, opportunities, and challenges ahead.Immunologic research · 2025Review
- Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive.Clinical and molecular hepatology · 2025Article
- Comprehensive biomarker profiling reveals distinct molecular signatures across stone types: a large-scale cross-sectional study in Southern China.Frontiers in physiology · 2025Article
- Review
- Role of biochemical markers and autoantibodies in diagnosis of early-stage primary biliary cholangitis.World journal of gastroenterology · 2023Article
- Laboratory risk factors for coexistent primary biliary cholangitis in patients with Sjögren's syndrome: a retrospective study.BMC gastroenterology · 2023Article
- The Role of Inflammation in Cholestatic Liver Injury.Journal of inflammation research · 2023Review
- Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?Frontiers in immunology · 2023Review
- Highly Increased Levels of Inter-α-inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver Diseases.Journal of clinical and translational hepatology · 2022Article
- The Role of Epigenetics in Primary Biliary Cholangitis.International journal of molecular sciences · 2022Review
- New insights on the role of human leukocyte antigen complex in primary biliary cholangitis.Frontiers in immunology · 2022Review
- Epigenetic Aspects and Prospects in Autoimmune Hepatitis.Frontiers in immunology · 2022Review
- Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.Frontiers in immunology · 2022Review
- The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases.Frontiers in immunology · 2021Review
- Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends.Clinical reviews in allergy & immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 4 countries.
Funding
Abstract
unlabelledThe cross-talk of cluster of differentiation (CD)40/CD40 ligand (CD40L) plays a key role in CD4(+) T-cell priming, B-cell terminal maturation, and immunoglobulin (Ig) class-switch recombination. Genetic defects in the CD40L lead to a disorder characterized by elevated concentrations of serum IgM and immunodeficiency. Patients with primary biliary cirrhosis (PBC) characteristically show circulating antimitochondrial antibodies (AMAs), liver-infiltrating autoreactive T lymphocytes against mitochondrial antigens, and high levels of IgM. We hypothesized that CD40L may play a key role in the pathogenesis of the elevated serum IgM and analyzed genetic and epigenetic modifications of the gene coding for CD40L in CD4(+) and CD8(+) T cells isolated from circulating mononuclear cells from PBC patients and healthy controls. We herein demonstrate significantly lower levels of DNA methylation of the CD40L promoter in CD4(+) T cells from PBC patients, as compared with controls, and this decreased methylation was inversely correlated with levels of serum IgM in PBC patients.
conclusionThe findings of an absence of genetic modifications of the CD40L gene, in concert with decreased DNA methylation of the CD40L promoter in PBC patients, suggests that environmental factors, rather than genetics, must play a major role in the pathogenesis of elevated serum IgM in PBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.